- 3. Special items
- 4. Sales
- 5. Cost of sales
- 6. Cost of materials
- 7. Personnel expenses
- 8. Selling, general and administrative expenses
- 9. Investment gain
- 10. Net interest
- 11. Other financial result
- 12. Taxes
- 13. Earnings per share
3. Special items
Net income attributable to shareholders of Fresenius SE & Co. KGaA for the year 2012 in the amount of €926 million includes several special items.
An expense in the amount of €17 million resulted from Fresenius Medical Care’s renegotiation of the license, distribution, manufacturing and supply agreement for iron products sold under the Venofer® brand and from a donation to the American Society of Nephrology.
The special item relating to the acquisition of Liberty Dialysis Holdings, Inc. by Fresenius Medical Care in an amount of €34 million is described in note 9, Investment gain.
Furthermore, net income attributable to shareholders of Fresenius SE & Co. KGaA for the year 2012 includes special items in the amount of -€29 million relating to the takeover offer to the shareholders of RHÖN-KLINIKUM AG.
The special items comprised the following:
€ in millions | EBIT | Investment gain | Other financial result | Net income attributable to shareholders of Fresenius SE & Co. KGaA |
---|---|---|---|---|
Earnings 2012, adjusted | 938 | |||
Venofer / donation Fresenius Medical Care | -86 | -17 | ||
Investment gain Fresenius Medical Care | 109 | 34 | ||
Financing costs RHÖN-KLINIKUM AG | -35 | -25 | ||
Other costs RHÖN-KLINIKUM AG | -6 | -4 | ||
Total special items | -92 | 109 | -35 | -12 |
Earnings 2012 according to U.S. GAAP 2012 | 926 |
The consolidated statement of income for the year 2011 ultimately included several special items relating to the acquisition of APP Pharmaceuticals, Inc. (since 2012: Fresenius Kabi USA, Inc.) in 2008. The table below reconciles adjusted earnings to earnings according to U.S. GAAP in 2011.
€ in millions | Other financial result | Net income attributable to shareholders of Fresenius SE & Co. KGaA |
---|---|---|
Earnings 2011, adjusted | 770 | |
Mandatory Exchangeable Bonds (mark-to-market) | -105 | -85 |
Contingent Value Rights (mark-to-market) | 5 | 5 |
Earnings 2011 according to U.S. GAAP 2011 |
690 |
For further information regarding Mandatory Exchangeable Bonds and Contingent Value Rights see note 11, Other financial result.
4. Sales